Education
About Us
Working with TipRanks
Follow Us
Dimerix Limited (AU:DXB)
ASX:DXB
DXB Stock Chart & Stats
AU$0.48
-AU$0.03(-5.00%)
At close: 4:00 PM EST
AU$0.48
-AU$0.03(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.34 - AU$0.79
Previous CloseN/A
Volume4.60M
Average Volume (3M)1.47M
Market Cap
AU$285.19M
Enterprise ValueAU$217.00M
Total Cash (Recent Filing)AU$68.28M
Total Debt (Recent Filing)AU$97.48K
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Mar 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding600,396,800
10 Day Avg. Volume1,720,426
30 Day Avg. Volume1,468,144
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)24.09
Price to Sales (P/S)256.86
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.46Price Target Upside204.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high top-line expansion indicates improving commercial traction or successful trial milestones; this durable revenue momentum can attract partners, support continued R&D investment and reduce reliance on dilutive financings if it persists over multiple reporting periods.
Low LeverageA very low debt burden provides long-term financial flexibility for a clinical‑stage biopharma: it lowers interest obligations, reduces refinancing risk during extended development cycles and preserves optionality to fund trials or pursue partnerships without immediate solvency pressure.
Cash ConversionOperating cash generation exceeding accounting losses shows effective cash conversion from operations, a durable sign managers can convert activities into cash. This supports near‑term funding of clinical programs and lessens dependence on immediate external capital if sustained.
Bears Say
Negative ProfitabilityPersistent negative operating and net margins reflect structural unprofitability typical of clinical-stage biotech but limit internal funding capacity. Over months, continued margin deficits increase financing needs and can dilute shareholder value if not reversed by milestones.
Very Negative ROEA sharply negative ROE indicates the company is destroying equity capital rather than generating returns, a durable weakness that raises questions about capital allocation effectiveness and heightens the likelihood of future equity raises to sustain development.
Free Cash Flow DeclineA drastic drop in free cash flow growth signals worsening cash sustainability and may force recurring external financing. Over a multi-month horizon this structural deterioration constrains investment flexibility and increases execution risk for costly clinical programs.
Dimerix Limited News
DXB FAQ
What was Dimerix Limited’s price range in the past 12 months?
Dimerix Limited lowest share price was AU$0.34 and its highest was AU$0.79 in the past 12 months.
What is Dimerix Limited’s market cap?
Dimerix Limited’s market cap is AU$285.19M.
When is Dimerix Limited’s upcoming earnings report date?
Dimerix Limited’s upcoming earnings report date is Mar 02, 2026 which is in 13 days.
How were Dimerix Limited’s earnings last quarter?
Dimerix Limited released its earnings results on Aug 27, 2025. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Dimerix Limited overvalued?
According to Wall Street analysts Dimerix Limited’s price is currently Undervalued.
Does Dimerix Limited pay dividends?
Dimerix Limited does not currently pay dividends.
What is Dimerix Limited’s EPS estimate?
Dimerix Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dimerix Limited have?
Dimerix Limited has 600,396,800 shares outstanding.
What happened to Dimerix Limited’s price movement after its last earnings report?
Dimerix Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Dimerix Limited?
Currently, no hedge funds are holding shares in AU:DXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dimerix Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.46 (204.17% Upside)
AU$1.46 (204.17% Upside)
Blogger Sentiment
Bullish
AU:DXB Sentiment 96%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.10%
12-Months-Change
Fundamentals
Return on Equity
-83.97%
Trailing 12-Months
Asset Growth
184.23%
Trailing 12-Months
Company Description
Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.
DXB Stock 12 Month Forecast
Average Price Target
AU$1.46
▲(204.17% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Orthocell Ltd
―
Immutep Ltd
―
Race Oncology Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---